Chronic morphologically verified gastritis, variants of course

Plotnikova E.Yu., Kutsaeva A.O., Sukhikh A.S., Baranova E.N., Sinkov M.A., Nikonorova M.A.

1) Kemerovo State Medical University, Kemerovo, Russia; 2) I.A. Kolpinsky Clinical Consultative and Diagnostic Center, Kemerovo, Russia; 3) Kemerovo State University, Laboratory of Physicochemical Studies of Pharmacologically Active and Natural Compounds, Kemerovo, Russia; 4) Research Institute of Complex Issues of Cardiovascular Diseases, Kemerovo, Russia; 5) Altai State Medical University, Barnaul, Russia

Background: Gastritis is a histological diagnosis, although its prevalence is decreasing in developed countries along with the prevalence of Helicobacter pylori infection. We identified H. pylori-positive (Hp+) and H. pylori-negative (Hp-) gastritis variants to analyze relationships that have not been adequately studied in previous studies.
Objective: Evaluation of the clinical, laboratory, and histological changes in the gastric mucosa in Hp+ and Hp- gastritis.
Materials and methods: We examined 122 patients (62 with Hp+ and 60 with Hp- gastritis) aged 20 to 65 years. In addition to conventional clinical and biochemical tests, the laboratory tests included the Gastropanel. For the diagnosis of Helicobacter pylori, 2-3 available methods were used for each patient. All study participants underwent esophagogastroduodenoscopy with morphological examination of biopsy specimens according to OLGA/OLGIM criteria. The vegetative status of the examined patients was assessed. All patients were prescribed treatment for gastritis, depending on the presence of Hp infection. Differences between the comparison parameters were considered statistically different at p≤0.05.
Results: Hp- gastritis was more often verified in the antral section, while Hp+ gastritis almost always affected both the antral section and the stomach body. Metaplasia according to OLGIM 0–I was observed only in 9 patients with Hp+ gastritis (p>0.05). In the vegetative status, vagotonia prevailed, in contrast to the control (p>0.05). All patients with Hp+ gastritis were prescribed anti-Helicobacter therapy. A number of patients chose a combination composition with the commercial name Pilobact® AM and bismuth tripotassium dicitrate for 14 days, had an eradication level of 87.4%. We conducted a pharmacochemical comparative analysis of the drugs included in Pilobact® AM with reference drugs and obtained their high comparability.
Conclusion: Significant differences in clinical and laboratory parameters in patients with Hp+ Hp- gastritis were revealed only in morphological data. One of the anti-Helicobacter treatment options can be the Pilobact® AM combination, which has proven both its high efficiency in clinical observations and pharmacochemical comparability with reference drugs.

Keywords

About the Authors

Ekaterina Yu. Plotnikova, Dr. Sci. (Med.), Professor, Department of Postgraduate Training and Nursing, Head of the Clinical Gastroenterology Course, Kemerovo State Medical University, Kemerovo, Russia; eka-pl@rambler.ru, SPIN-code: 4346-5012, ORCID: https://orcid.org/0000-0002-6150-1808, Scopus Author ID: 57193910407 (corresponding author)
A.O. Kutsaeva, Gastroenterologist, I.A. Kolpinsky Clinical Consultative and Diagnostic Center, Kemerovo, Russia; dr.kytsaeva@vk.com, ORCID: https://orcid.org/0009-0006-2396-3880
A.S. Sukhikh, Cand. Sci. (Med.), Head of the Laboratory of Physicochemical Studies of Pharmacologically Active and Natural Compounds, Kemerovo State University, Kemerovo, Russia; suhih_as@list.ru, ORCID: https://orcid.org/0000-0001-9300-5334
E.N. Baranova, Cand. Sci. (Med.), Associate Professor, Department of Hospital Therapy and Clinical Pharmacology, Kemerovo State Medical University, Kemerovo, Russia; bevgn@rambler.ru
M.A. Sinkov, Cand. Sci. (Med.), Cardiovascular Surgeon, Research Institute of Complex Issues of Cardiovascular Diseases, Kemerovo, Russia;
fox2you@mail.ru, ORCID: https://orcid.org/0000-0002-2494-8694
M.A. Nikonorova, Dr. Sci. (Med.), Associate Professor, Professor at the Department of Infectious Diseases with the Course of Continuous Professional Education, Altai State Medical University, Barnaul, Russia; ma.nikulina@mail.ru, ORCID: https://orcid.org/0000-0001-6621-9310, Scopus Author ID: 57222869049

Similar Articles